Drug Trial Radar · NCT00134563
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,088
Actual
Start
Sep 2004
Primary completion
Jul 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS). Secondary objectives were: * to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burden of disease as measured by Magnetic Resonance Imaging \[MRI\] and patient-reported fatigue; * to evaluate the safety and tolerability of teriflunomide.
Conditions
- Multiple Sclerosis
Interventions
TeriflunomideDrug
Film-coated tablet Oral administration
Placebo (for teriflunomide)Drug
Film-coated tablet Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate [ARR]: Poisson Regression EstimatesTime frame: 108 weeks
Locations
21 sites in 21 countries. Site status is shown where the registry gives one.
Sanofi-Aventis
Bridgewater, New Jersey
Sanofi-Aventis Austria
Vienna, Austria
sanofi-aventis, Canada
Laval, Canada
Sanofi-Aventis
Santiago, Chile
Sanofi-Aventis Administrative Office
Prague, Czechia
sanofi-aventis Denmark
Hørsholm, Denmark
Sanofi-Aventis Administrative Office
Tallinn, Estonia
sanofi-aventis Finland
Helsinki, Finland
sanofi-aventis France
Paris, France
Sanofi-Aventis Deutschland GmbH
Berlin, Germany
Sanofi-Aventis
Milan, Italy
Sanofi-Aventis
Gouda, Netherlands
Sanofi-Aventis
Lysaker, Norway
sanofi-aventis Poland
Warsaw, Poland
Sanofi-Aventis
Porto Salvo, Portugal
Sanofi-Aventis
Moscow, Russia
Sanofi-Aventis
Bromma, Sweden
Sanofi-Aventis Switzerland
Geneva, Switzerland
sanofi-aventis Turkey
Istanbul, Turkey (Türkiye)
Sanofi-Aventis Administrative Office
Kiev, Ukraine
sanofi-aventis UK
Guildford, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.